Oscient Pharmaceuticals to Participate in the Natixis Bleichroeder Hidden Gems Conference
© Business Wire 2005
01.10.2007 19:31:25
(live-PR.com) - www.oscient.com - Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) will participate in the Natixis Bleichroeder Hidden Gems Conference on Monday, October 8, 2007 in New York City. The Company's President and CEO, Steven Rauscher, will provide an overview of the Company including details on the recent market performance of ANTARA(R) (fenofibrate) capsules and FACTIVE(R) (gemifloxacin mesylate) tablets in the U.S.
The
presentation will begin at 11:30 AM ET on Monday and will be webcast through the Company's website at www.oscient.com. An archive of the webcast will also be available for 90 days.
About Oscient Pharmaceuticals
Oscient Pharmaceuticals Corporation is a commercial-stage pharmaceutical company marketing two FDA-approved products with its national primary care sales force. ANTARA(R) (fenofibrate) capsules is indicated for the adjunct treatment of hypercholesterolemia (high blood cholesterol) and hypertriglyceridemia (high triglycerides) in combination with diet. FACTIVE(R) (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and community-acquired pneumonia of mild to moderate severity. Oscient also has a novel, late-stage antibiotic candidate, Ramoplanin, under investigation for the treatment of Clostridium difficile-associated disease (CDAD).
For important information regarding the safety and use of ANTARA and FACTIVE, please see the full prescribing information available at www.antararx.com and www.factive.com.
Oscient Pharmaceuticals Corporation
Investor Relations:
Christopher Taylor, 781-398-2466
or
Media Relations:
Sarah Emond, 781-398-2544
The
|
|
About Oscient Pharmaceuticals
Oscient Pharmaceuticals Corporation is a commercial-stage pharmaceutical company marketing two FDA-approved products with its national primary care sales force. ANTARA(R) (fenofibrate) capsules is indicated for the adjunct treatment of hypercholesterolemia (high blood cholesterol) and hypertriglyceridemia (high triglycerides) in combination with diet. FACTIVE(R) (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and community-acquired pneumonia of mild to moderate severity. Oscient also has a novel, late-stage antibiotic candidate, Ramoplanin, under investigation for the treatment of Clostridium difficile-associated disease (CDAD).
For important information regarding the safety and use of ANTARA and FACTIVE, please see the full prescribing information available at www.antararx.com and www.factive.com.
Oscient Pharmaceuticals Corporation
Investor Relations:
Christopher Taylor, 781-398-2466
or
Media Relations:
Sarah Emond, 781-398-2544
